bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.09.30.754912

Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments

Brown, B. R. P.·Li, X.·Grasty, M. R.·Miranker, A. D.·Gursoy, G.
View original source ↗Export metadata ↓

Abstract

Cerebrospinal fluid (CSF) contains brain derived proteins that can be leveraged as biomarkers for Alzheimer's disease (AD) and other neurodegenerative diseases. However, converting protein intensities to a disease signal remains a challenge because physiology driven changes to the localization of proteins across CSF subcompartments are obscured when CSF is analyzed alone. Where subcompartment data, such as that from extracellular vesicles (EVs), are also measured, separate but parallel analyses of EVs and CSF can obscure their shared disease signal. Here, we present an integrated matrix factorization approach that combines proteomic signals from matched CSF and phosphatidylserine exposed EVs and nanoparticles (EVps). In a ROS/MAP cohort of 48 participants, integrating CSF and EVps signals improved biological concordance across compartments and increased the number of candidate proteins distinguishing participants with AD from controls. Notably, the joint signal identified as many brain related biomarker candidates as studies using substantially larger cohorts. By demonstrating that integration of CSF and EVps proteomes maximizes information from limited samples, this framework offers a path toward more efficient biomarker discovery across two compartments increasingly leveraged in neurodegenerative disease research.

Explore related subjects

systems biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Brown, B. R. P., Li, X., Grasty, M. R., Miranker, A. D., Gursoy, G.. 2026-10-02. Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments. https://doi.org/10.64898/2026.09.30.754912

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Amino Acid Metabolic Signature Links Pediatric Environmental Enteric Dysfunction to Maternal-Fetal Growth Restriction Across Two Independent Cohorts

Environmental Enteric Dysfunction (EED) is a leading contributor to childhood stunting. Most EED literature derives from postnatal pediatric cohorts, leaving unclear how much of the metabolic signature reflects acquired intestinal pathology versus growth restriction originating earlier. We applied genome-scale metabolic modeling to explore whether metabolic features of pediatric EED overlap with those of maternal plasma proteomes associated with adverse early-life growth. Duodenal transcriptomics from the Study of Environmental Enteropathy and Malnutrition (SEEM; 52 children with EED, 24 controls) and maternal plasma proteomics from the Alliance for Maternal and Newborn Health Improvement (AMANHI; n = 2,485 pregnant women) were integrated with the Human1 model using Reaction Inclusion by Parsimony and Transcript Distribution (RIPTiDe), followed by flux sampling and Linear Discriminant Analysis, across five growth-related proxies (small-for-gestational-age, low birth weight, preterm birth, stunting, and wasting). Amino acid and nucleotide metabolism were prominent among the top discriminating reactions in EED and most proxies. Of the 50 reactions distinguishing EED from control, 24 (48%) were among the top reactions in at least one proxy, and 19 (38%) with low birth weight, the largest of any proxy. These exploratory findings suggest shared metabolic pathways across tissues and life stages and motivate longitudinal studies.

systems biology↗
bioRxiv2026

Network-guided identification of candidate biomarkers for COPD-associated comorbidities using deep learning and real-world transcriptomic data

Chronic obstructive pulmonary disease (COPD) frequently coexists with infections, metabolic disease, cardiovascular disease, inflammatory lung injury and lung cancer. Molecular markers derived by comparing a comorbidity with healthy controls need not identify the transition from an established COPD state to that comorbidity. We therefore developed a two-stage computational strategy that asks a narrower question: which proteins can distinguish COPD samples from samples annotated with a specific COPD-associated comorbidity? First, a Human Protein Network (HPN; 17,302 proteins and 492,195 relationships) was encoded by 20 graph-derived features. A convolutional-neural-network ensemble, termed the functional-distance model (FDM), was trained on known drug-target-indication relationships. Stored training-set predictions yielded an apparent balanced accuracy of 0.811 and Matthews correlation coefficient (MCC) of 0.627; these values describe resubstitution performance and are not an independent estimate of generalization. The COPD-centred network search evaluated 2,645 nearby proteins and retained 224 candidates using a COPD FDM score above 0.50. Candidate expression was then tested in independently assembled public patient-derived transcriptomic data using simple one-feature classifiers and cross-validation. The resulting exploratory panel contained GTF2I for bacterial infection, UBXN7 for type 2 diabetes, LIFR for hypertension, SRGN for lung neoplasm and FGF4 for pneumonitis. Across the saved cross-validation predictions, balanced accuracy ranged from 0.838 to 0.970 and MCC from 0.726 to 0.941. SRGN has direct experimental support in non-small-cell lung cancer, whereas the remaining candidates have varying indirect mechanistic support and should be regarded as hypotheses rather than established disease biomarkers. This work demonstrates an orthogonal discovery framework in which network-based functional prioritization and patient-derived molecular discrimination constrain one another. Its main contribution is methodological: it provides a reusable strategy for generating comorbidity-specific biomarker hypotheses from an index-disease state. Prospective longitudinal cohorts are required before claims of progression prediction or clinical utility can be made.

systems biology↗
bioRxiv2026

An integrated identifiability and metabolic flux analysis workflow for reducing and repairing dynamic CHO metabolic models

Over-parametrized kinetic-metabolic models can fit available data accurately yet still yield unreliable parameter estimates and output uncertainties. We developed an integrated workflow that combines Fisher information matrix-based identifiability analysis diagnostics, uncertainty propagation, and metabolic flux analysis (MFA) to reduce model size and assess the transferability of a kinetically constrained dynamic flux balance analysis (dFBA) model of CHO perfusion culture. Using Control medium data, the dFBA model size was reduced from 48 to 43 kinetic parameters while maintaining performance across 23 measured extracellular species. The reduced models transferability was assessed by predicting cell behavior in an amino acid-supplemented medium (Medium C), which lowered the specific growth rate while increasing specific productivity. The reduced model successfully predicted viable cell density, antibody titer, and supplemented amino acids for Medium C but failed to capture the reversal of glutamate metabolism and the increase in lactate production. Output uncertainty quantification identified structural gaps rather than parameter uncertainty as the underlying cause of prediction failures, with 79% of Medium C experimental points lying outside the 95% parameter-propagated interval. Stoichiometric MFA linked the Medium C phenotype to increased amino acid catabolism, identified the intracellular sources for glutamate and lactate production, and enabled estimation of two new rate-constants for their production directly from stoichiometric flux, rather than fitted to data. MFA-guided repair reduced glutamate and lactate NRMSE in Medium C by 64% and 36%, respectively. The workflow provides a systematic strategy for improving model identifiability and using MFA to diagnose and repair structural discrepancies.

systems biology↗